Evidence map›Paper›PMID 35382766›Full record

ArticleBMC nephrology2022

Tolerability and epidemiology of nephrotoxicity associated with conventional amphotericin B therapy: a retrospective study in tertiary care centers in Palestine.

Yusri Abdel-Hafez, Hani Siaj, Mohammad Janajri, Yazan Abu-Baker, Zaher Nazzal, Zakaria Hamdan, Rabee Adwan, Banan M Aiesh, Ahmad I Anaya

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC nephrology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Diagnosis and Treatment of Invasive Candidiasis.Antibiotics (Basel, Switzerland) · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 3 countries.

Yusri Abdel-HafezFaculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine.
Hani SiajFaculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine.
Mohammad JanajriFaculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine.
Yazan Abu-BakerFaculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine.
Zaher NazzalCommunity Medicine, Department of Family and Community Medicine, Faculty of Medicine and Health Sciences, An-Najah National University, Box 7, 707, Nablus, Palestine. znazzal@najah.edu.
Zakaria HamdanInternal Medicine Department, An-Najah National University Hospital, Box 7, 707, Nablus, Palestine. z.hamdan@najah.edu.
Rabee AdwanInfectious Diseases Unit, Makassed Charitable Society Hospital, East Jerusalem, Palestine.
Banan M AieshInfection Control Department, An-Najah National University Hospital, Nablus, Palestine.
Ahmad I AnayaInternal Medicine Department, An-Najah National University Hospital, Nablus, Palestine.
An-Najah National University · PSAl-Makassed Islamic Charitable Society Hospital · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn the light of recent years, an increase in the number of life-threatening infections due to various fungi has been observed, especially in tertiary care centres. With Amphotericin B labelled as the first choice in treating these infections, one of its common side effects, nephrotoxicity, along with hypokalemia, were studied to determine the epidemiology, risk factors, and protective measures. METHODOLOGY: The study was a retrospective observational chart review study in which patients were receiving conventional Amphotericin B in two tertiary hospitals in Palestine from January 2018 to December 2020 were evaluated for the development of hypokalemia and nephrotoxicity; according to the KDIGO criteria. A total of 117 patients were included in the study. Patients who have received the drug intermittently, in fewer than two doses, through non-IV routes and patients under the age of 12 were excluded. The data collected included, but were not limited to, age, gender, comorbidities, Amphotericin B treatment details, medications, COVID-19 status, risk factors, and hypothesized protective measures.

resultsThe incidence of conventional Amphotericin B nephrotoxicity and hypokalemia was 46% and 33%, respectively. With a roughly equal representation of both genders and a median age of 52 years in a range of 13-89. No association between the variables and the development of nephrotoxicity was found. However, a 3.4 increased risk (p-value = 0.01) of developing hypokalemia in females compared to males was observed.

conclusionOur research has shown a relatively lower yet consistent, incidence of conventional amphotericin B nephrotoxicity and hypokalemia compared to literature with gender being a risk factor for developing hypokalemia.

Indexed as

Amphotericin BCOVID-19AdolescentAdultAgedAged, 80 and overAntifungal AgentsFemaleHumansMaleMiddle AgedRetrospective StudiesTertiary Care CentersYoung AdultAmphotericin BAntifungal AgentsAmphotericin BAntifungalHypokalemiaNephrotoxicity

Identifiers

PMID35382766
PMCPMC8982299
OpenAlexW4225695308

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.